Safety of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis as used in Clinical Practice: Results from the ARTIS Programme
Ann Rheum Dis. 2023 doi: 10.1136/ard-2022-223762 Epub ahead of print
Nationwide register-based cohort study corroborates and extends previous evidence that the currently available biologic/targeted synthetic DMARDs have an acceptable and, on the whole, similar safety profile.
Patient Characteristics Influence the Choice of Biological Drug in RA, and will make non-TNFi Biologics appear more Harmful than TNFi Biologics
Ann Rheum Dis 2018; 77:650–57 DOI: 10.1136/annrheumdis-2017-212395Analysis of patient characteristics revealed that older and less healthy patients with RA were more likely to receive non-TNFi bDMARDs as a first bDMARD compared to other treatments.This study aimed to describe patient characteristics at initiation of bDMARD treatment at two-time points: first bDMARD initiation and switch to second bDMARD after TNFi treatment. The second aim of the study was to estimate the potential of treatment channelling to confound results in comparative treatment studies i...